Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 27;6:94. doi: 10.1038/s41698-022-00335-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Violin dot plots displaying the mean DSS_asym values for the whole cohort (upper graph) and each drug for the respective sample (lower graph; blue line: mean). The sample of interest (here, case #1 relapse 3) is marked in orange. b Waterfall plot sorting all tested drugs for the case #1 relapse 3 sample upon their DSS_asym values, starting with the highest on the left. c Dot plots depicting the DSS_asym values for the indicated drugs for all successfully screened samples. The sample of interest (here, case #1 relapse 3) is marked in orange. All three MET inhibitors (merestinib, crizotinib, foretinib) show above-average responses, whereas the three NTRK inhibitors all have a DSS_asym of or close to 0. d Copy-number profiles of the FF samples reveal an acquired (or selected) MET amp in the plot for relapse 3.